Comparison of efficiency of bambuterol and salmeterol

  • Olof Selroos
Conference paper


The once-daily oral bronchodilator bambuterol and the twice-daily inhaled bronchodilator salmeterol have been compared in only a few studies. In placebo-controlled studies, both bronchodilators have been found clinically effective and with few side-effects. In a double-blind, randomized 6-week parallel-group study in 117 patients with nocturnal asthma and using inhaled or oral steroids, no difference was found in efficacy between bambuterol 20 mg once daily in the evening and salmeterol 50 µg b.i.d. (morning and evening PEF, nocturnal awakenings). Similar results were seen in a double-blind, crossover study in 12 patients comparing 10 mg bambuterol in the evening with salmeterol 50μg in the evening for 2 weeks each. In a small, double-blind crossover study in 15 patients with reversible airway obstruction, bambuterol 20 mg once daily in the morning was compared with placebo for one week each. The patients were thereafter treated openly for one week with 50 μg salmeterol b.i.d. In steady state, on day 8, the 12- and 24-hour FEV1 values and the maximum FEV1 values were not significantly different after treatment with bambuterol or salmeterol. No differences in side-effects were seen. Further comparative double-blind, controlled studies are warranted.


Peak Expiratory Flow Nocturnal Asthma Morning Peak Expiratory Flow Reversible Airway Obstruction Evening Peak Expiratory Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Olsson OAT, Svensson LA (1984) New lipophilic terbutaline ester prodrugs with long effect duration. Pharmaceut Res 1: 19–23CrossRefGoogle Scholar
  2. 2.
    Svensson LA (1987) Bambuterol: a prodrug-prodrug with built-in hydrolysis brake. Acta Pharm Suec 24: 333–341PubMedGoogle Scholar
  3. 3.
    van den Berg W, Alanko K, Sahlström K, Järvinen M, Mikkola E, Jansson C (1989) Bambuterol once every evening 10 mg and 20 mg compared with terbutaline 5 mg three times daily. Eur Respir J 2 [Suppl 8]: 812sGoogle Scholar
  4. 4.
    Persson G, Pahlm O (1990) Efficacy and safety of bambuterol once daily in comparison with terbutaline t.i.d. Clin Exp Allergy 20 [Suppl 1]: 35Google Scholar
  5. 5.
    Larsen K, Schmekel B (1993) Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets. Eur J Clin Pharmacol 45: 303–305PubMedCrossRefGoogle Scholar
  6. 6.
    Selroos O, Sahlström K, Backman R, Laxmayr L (1992) Bronchodilating properties of once daily bambuterol in asthma. J Allergy Clin Immunol 89: P339Google Scholar
  7. 7.
    Persson G, Baas A, Knight A, Larsen B, Olsson H (1995) One month treatment with the once daily oral 132-agonist bambuterol in asthmatic patients. Eur Respir J 8: 34–39PubMedCrossRefGoogle Scholar
  8. 8.
    D’Alonzo GE, Smolensky MH, Feldman S, Gnosspelius Y, Karlsson K (1995) Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration. Chest 107: 406–412PubMedCrossRefGoogle Scholar
  9. 9.
    Petrie GR, Chookang JY, Hassan WU et al (1993) Bambuterol: effective in nocturnal asthma. Respir Med 87: 581–585PubMedCrossRefGoogle Scholar
  10. 10.
    Ullman A, Svedmyr N (1988) Salmeterol, a new long-acting inhaled β2 adrenoceptor agonist: a comparison with salbutamol in adult asthmatic patients. Thorax 43: 674–678PubMedCrossRefGoogle Scholar
  11. 11.
    Dahl R, Earnshaw JS, Palmer JBD (1991) Salmeterol: a four week study of long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J 4: 1178–1184PubMedGoogle Scholar
  12. 12.
    Britton MG, Earnshaw JS, Palmer JBD (1992) A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 5: 1062–1067PubMedGoogle Scholar
  13. 13.
    Pearlman DS, Chervinsky P, LaForce C et al (1992) A comparison of salmeterol with albuterol in the treatment of mild-moderate asthma. N Engl J Med 327: 1420–1425PubMedCrossRefGoogle Scholar
  14. 14.
    Palmer JBD, Stuart AM, Shepherd GL, Viskum K (1992) Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease — a 3 month comparison of the efficacy and safety of twice daily salmeterol (100µg) with salmeterol (50 µg). Respir Med 86: 409–417PubMedCrossRefGoogle Scholar
  15. 15.
    Muir JF, Bertin L, Georges D (1992) Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial. Eur Respir J 5: 1197–1200PubMedGoogle Scholar
  16. 16.
    International consensus report on the diagnosis and management of asthma (1992) Clin Exp Allergy 22 [Suppl]: 1–72Google Scholar
  17. 17.
    Wallaert B, Ostinelli J, Arnould B (1995) Long acting β2 agonists: a comparison of oral bambuterol and inhaled salmeterol in asthmatic patients with nocturnal symptoms. Eur Respir J 8 [Suppl 19]: 1sGoogle Scholar
  18. 18.
    Justicia JL, Segurado E, Munos MA et al (1995) Salmeterol versus bambuterol in nocturnal asthma. Allergy 50 [Suppl 26]: 315Google Scholar

Copyright information

© Springer-Verlag/Wien 1998

Authors and Affiliations

  • Olof Selroos
    • 1
  1. 1.Mjölbolsta HospitalFinland

Personalised recommendations